The study, published in the Journal of the National Cancer Institute found that in addition to protecting against 80% of cervical cancers, the new Gardasil-9 has the potential to protect against nearly 19,000 other cancers diagnosed in the United States.
The new 9-valent human papillomavirus (HPV) vaccine, can potentially prevent 80% of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus.
In addition to protecting against 80% of cervical cancers, the new 9-valent HPV vaccine, which includes 7 cancer causing HPV-types—16,18, 31, 33, 45, 52, and 58—has the potential to protect against nearly 19,000 other cancers diagnosed in the United States, including anal, oropharyngeal, and penile cancers. This is a 13% increase in protection against HPV-related cancers in comparison to the first vaccines on the market, Gardasil and Cervarix, which protected against HPV types 16 and 18. These findings come from a 7-center study published in the Journal of the National Cancer Institute. The CDC initiated the research effort, in conjunction with Cedars-Sinai.
Read the article on MedicalXpress: http://bit.ly/1HbBUaD
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More